Barinthus Biotherapeutics plc
NASDAQ: BRNS0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- William James Enright
- Employees
- 105
- Headquarters
- Didcot, United Kingdom
- IPO year
- 2021
- Market cap
- $27.0M
- Website
- https://www.barinthusbio.com
Loading BRNS…
Loading profile data…Frequently asked questions about BRNS
What does Barinthus Biotherapeutics plc (BRNS) do?
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical firm, is dedicated to pioneering innovative T-cell immunotherapies. These cutting-edge treatments are engineered to harness the body's own immune system to effectively combat chronic infectious diseases, autoimmune disorders, and various cancers. The company is actively progressin...
Where does BRNS trade?
Barinthus Biotherapeutics plc (BRNS) trades on the NASDAQ Global Market.
What sector is BRNS in?
Barinthus Biotherapeutics plc (BRNS) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Barinthus Biotherapeutics plc?
William James Enright is the chief executive officer of Barinthus Biotherapeutics plc (BRNS).
Where is Barinthus Biotherapeutics plc headquartered?
Barinthus Biotherapeutics plc is headquartered in United Kingdom.
Does BRNS pay a dividend?
Barinthus Biotherapeutics plc (BRNS) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did BRNS go public?
Barinthus Biotherapeutics plc (BRNS) completed its initial public offering in 2021.
Is BRNS an ADR?
Yes — BRNS is an American Depositary Receipt; its underlying shares trade on a non-US exchange. Barinthus Biotherapeutics plc reporting and dividends follow the underlying issuer.